ArticleJournal of translational medicine2026
The hidden effects of metabolism-disrupting agents on alcohol-related liver disease risk: an integrated epidemiological, machine learning, and network toxicology Analysis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividual susceptibility to alcohol-related liver disease (ALD) varies substantially despite similar alcohol consumption patterns. Emerging evidence suggests metabolism-disrupting agents (MDAs) may synergistically amplify alcohol-induced hepatotoxicity, yet population-level evidence remains limited. This study investigated associations between 40 MDAs and ALD risk using integrated analytical approaches.
methodsWe analyzed 13,472 National Health and Nutrition Examination Survey participants (2005-2016). Forty MDAs spanning per- and polyfluoroalkyl substances, phenolic compounds, phthalate metabolites, polycyclic aromatic hydrocarbon metabolites, and volatile organic compound metabolites were measured using standardized protocols. Multivariable logistic regression assessed MDA-ALD associations. Restricted cubic splines characterized dose-response relationships. Subgroup analyses identified vulnerable populations by sex, age, race/ethnicity, body mass index, and hyperlipidemia status. Machine learning algorithms including LightGBM were developed with nested cross-validation (to prevent data leakage during feature selection) to identify predictive biomarkers. Network toxicology integrated computationally predicted MDA targets with ALD gene expression data (GEO GSE28619), followed by pathway enrichment analyses.
resultsThree MDAs demonstrated robust positive associations: benzylmercapturic acid (BMA; OR: 1.56, 95% CI: 1.31-1.86), perfluorohexanesulfonic acid (PFHxS; OR: 1.56, 95% CI: 1.28-1.90), and benzophenone-3 (BP-3; OR: 1.40, 95% CI: 1.15-1.72). BMA and PFHxS exhibited linear dose-response relationships without thresholds, while ATCA showed an inverted U-shaped pattern and BP-3 displayed a plateau pattern. Phenolic compounds and phthalates demonstrated stronger associations in females. LightGBM achieved optimal performance (cross-validation AUC: 0.760, test AUC: 0.706), identifying N-acetyl-S-(3-hydroxypropyl)-L-cysteine, N-acetyl-S-(N-methylcarbamoyl)-L-cysteine, and mono-carboxyoctyl phthalate as key predictive biomarkers, including compounds not significant in regression. Network analysis identified 192 shared genes with enrichment in neuroactive ligand-receptor interactions and nuclear receptor pathways (PPARα/γ, PXR, FXR).
conclusionsSpecific MDAs demonstrated significant ALD associations through complementary approaches. Evidence suggests MDAs may function as signal disruptors within neuro-endocrine-immune networks, with pathways paralleling alcohol-induced hepatotoxicity. Findings underscore incorporating environmental assessments into ALD risk stratification and highlight needs for prospective validation and mechanistic studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.